A large national and international study has identified dozens of blood proteins linked to prostate cancer risk, some shared across populations, some unique to specific groups.
To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department of Radiation Oncology developed the PSA Control Tower, an intelligent monitoring tool designed to support clinicians in keeping a close, ongoing watch over patients after treatment.
